Page 158 - Read Online

Page 12 of 17 Ghunaim et al. Vessel Plus 2023;7:29 https://dx.doi.org/10.20517/2574-1209.2023.112

Copyright
© The Author(s) 2023.

REFERENCES
1. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and
therapeutics. J Cell Physiol 2019;234:16812-23. DOI
2. Bollano E, Redfors B, Rawshani A, et al. Temporal trends in characteristics and outcome of heart failure patients with and without
significant coronary artery disease. ESC Heart Fail 2022;9:1812-22. DOI PubMed PMC
3. Bakaeen FG, Gaudino M, Whitman G, et al. 2021: The American Association for thoracic surgery expert consensus document:
coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. J Thorac Cardiovasc Surg 2021;162:829-
50.e1. DOI
4. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA 2020;324:488-504. DOI
PubMed
5. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the
American Heart Association. Circ Heart Fail 2013;6:606-19. DOI PubMed PMC
6. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-327.
DOI PubMed
7. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational research programme: regional differences and 1-year follow-up
results of the heart failure pilot survey (ESC-HF pilot). Eur J Heart Fail 2013;15:808-17. DOI
8. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J
2001;22:228-36. DOI
9. Del Buono MG, Moroni F, Montone RA, Azzalini L, Sanna T, Abbate A. Ischemic cardiomyopathy and heart failure after
acute myocardial infarction. Curr Cardiol Rep 2022;24:1505-15. DOI PubMed PMC
10. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the american heart
association. Circulation 2022;145:e153-639. DOI
11. Lewsey SC, Breathett K. Racial and ethnic disparities in heart failure: current state and future directions. Curr Opin Cardiol
2021;36:320-8. DOI PubMed PMC
12. Cascino TM, Colvin MM, Lanfear DE, et al. Racial inequities in access to ventricular assist device and transplant persist after
consideration for preferences for care: a report from the REVIVAL study. Circ Heart Fail 2023;16:e009745. DOI PubMed PMC
13. Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J 2019;40:3859-68c. DOI
14. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med
2011;364:1607-16. DOI PubMed PMC
15. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med
2016;374:1511-20. DOI PubMed PMC
16. Carson P, Wertheimer J, Miller A, et al. The STICH trial (surgical treatment for ischemic heart failure): mode-of-death results. JACC
Heart Fail 2013;1:400-8. DOI PubMed PMC
17. Kim HM, Hwang IC, Choi W, Yoon YE, Cho GY. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart
failure with reduced ejection fraction. Sci Rep 2021;11:22342. DOI PubMed PMC
18. Lim AH, Abdul Rahim N, Zhao J, Cheung SYA, Lin YW. Cost effectiveness analyses of pharmacological treatments in heart failure.
Front Pharmacol 2022;13:919974. DOI PubMed PMC
19. Völz S, Redfors B, Angerås O, et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery
bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry
(SCAAR). Eur Heart J 2021;42:2657-64. DOI PubMed PMC
20. Sun LY, Gaudino M, Chen RJ, Bader Eddeen A, Ruel M. Long-term outcomes in patients with severely reduced left ventricular
ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting. JAMA Cardiol 2020;5:631-41.
DOI PubMed PMC
21. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in patients with multivessel coronary artery disease
and severe left ventricular systolic dysfunction: everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation
2016;133:2132-40. DOI PubMed PMC
22. Wolff G, Dimitroulis D, Andreotti F, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with
reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail 2017;10:e003255. DOI
23. Neumann A, Serna-Higuita L, Detzel H, et al. Off-pump coronary artery bypass grafting for patients with severely reduced
ventricular function-A justified strategy? J Card Surg 2022;37:7-17. DOI
24. Serruys PW, Kogame N, Katagiri Y, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients
with three-vessel disease: two-year follow-up of the SYNTAX II study. EuroIntervention 2019;15:e244-52. DOI
25. Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med
2022;387:1351-60. DOI PubMed